Li Jian, Jia Ying-bin, Cai Chao-nong, Guan Xiao-dong, Li Pei-ping, Xie Yu-yan, Zhang Bai-meng
The Third Department of General Surgery, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Nov;15(11):1171-4.
To evaluate whether neutrophil-lymphocyte ratio(NLR) predicts risk of recurrence in patients with advanced colon cancer undergoing curative resection followed by adjuvant chemotherapy.
A total of 149 patients with advanced colon cancer undergoing curative resection followed by adjuvant chemotherapy(FOLFOX6 protocol) were included. NLR was calculated preoperatively and before chemotherapy. The changes in NLR and the predictive value of NLR for prognosis were analyzed.
The NLR of 149 patients was 2.8±1.5. NLR of 3.5 was identified according to the ROC curve. NLR<3.5 and NLR≥3.5 were classified as low and high NLR group, respectively. The 5-year recurrence-free survival(RFS) of patients with high preoperative NLR(n=22) was significantly worse than that of those with low preoperative NLR(n=127)(50.9% vs. 76.4%, P=0.025). The difference of 5-year RFS between high pre-chemotherapy NLR group(n=34) and low pre-chemotherapy NLR group(n=115) was statistically significant(50.1% vs. 71.4%, P=0.032). The 5-year RFS was 79.5% in patients with low preoperative NLR converting to high pre-chemotherapy NLR(n=16), similar to the group with high pre-chemotherapy group(P=0.077). The 5-year RFS was 17.7% in patients with high preoperative NLR reverting to low pre-chemotherapy NLR(n=12), similar to the group with low pre-chemotherapy group(P=0.978). There was significant difference in 5-year RFS between the postoperatively elevated group and postoperatively decreased group(P=0.036).
An elevated blood NLR may be a biomarker of poor RFS in patients with advanced colon cancer after curative resection and chemotherapy.
评估中性粒细胞与淋巴细胞比值(NLR)是否可预测接受根治性切除及辅助化疗的晚期结肠癌患者的复发风险。
纳入149例接受根治性切除及辅助化疗(FOLFOX6方案)的晚期结肠癌患者。术前及化疗前计算NLR。分析NLR的变化及其对预后的预测价值。
149例患者的NLR为2.8±1.5。根据ROC曲线确定NLR为3.5。NLR<3.5和NLR≥3.5分别分为低NLR组和高NLR组。术前高NLR组(n=22)患者的5年无复发生存率(RFS)显著低于术前低NLR组(n=127)(50.9%对76.4%,P=0.025)。化疗前高NLR组(n=34)与化疗前低NLR组(n=115)的5年RFS差异有统计学意义(50.1%对71.4%,P=0.032)。术前低NLR转为化疗前高NLR组(n=16)患者的5年RFS为79.5%,与化疗前高NLR组相似(P=0.077)。术前高NLR恢复为化疗前低NLR组(n=12)患者的5年RFS为17.7%,与化疗前低NLR组相似(P=0.978)。术后升高组与术后降低组的5年RFS有显著差异(P=0.036)。
血液NLR升高可能是根治性切除及化疗后晚期结肠癌患者RFS不良的生物标志物。